
Overview
Background
Associate Professor Joy Wolfram leads an extracellular vesicle research program with the goal of developing innovative approaches that bring the next generation of medicines directly to the clinic to alter the trajectory of life-threatening diseases, improve patient outcomes, and prolong healthy lifespans. Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, Australia (#41 in Best Global Universities, U.S. News & World Report).
MISSION
1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer
2) Save lives by manufacturing at scale, by delivering national manufacturing innovation and a skilled workforce
3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine
Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional pharmaceuticals due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading of extracellular vesicles to develop therapeutics.
FOCUS AREAS
1) Developing improved methods for extracellular vesicle isolation from human biofluids
2) Designing hybrid drug delivery systems with extracellular vesicle and synthetic components for a ‘best-of-both-worlds’ approach to treat cardiovascular disease and aging kidney disease
3) Understanding the role of extracellular vesicles in cancer immunoevasion and metastasis
The research program has resulted in more than 100 publications in journals, such as, Nature Nanotechnology, Materials Today, and Nature Reviews Materials. These publications have been cited 18,800 times (Google Scholar). The Wolfram Laboratory has collaborated with 160 universities and industry partners across 45 countries (Scopus). The research program has also been featured in more than 100 presentations at scientific meetings, including 90+ invited talks and nine international keynote talks.
Wolfram is actively involved in community outreach and education, including in her previous roles as the Chair of an education and outreach working group of the National Institutes of Health in the United States and the Associate Program Director of the PhD Program in Regenerative Sciences at Mayo Clinic (Best Hospital in the World, Newsweek). As a TED speaker, she strives to bring science to a wide audience.
She has received 40+ awards from nine countries, including the 2016 Amgen Scholars Ten to Watch List (best and brightest up-and-comers in science and medicine across 42 countries), the 2019 Forbes 30 under 30 list in Health Care in the United States/Canada, the 2019 shortlist for the Nature Research Award for Inspiring Science (one of ten worldwide), and the 2021 Finnish Expatriate of the Year (past recipients include Nobel Memorial Prize winners, Millennium Technology Prize winners, and Formula 1 drivers). She is in the top 1% of researchers worldwide in the categories of ‘Biology & Biochemistry’ and ‘Pharmacology & Toxicology' (Essential Science Indicators, 2023) and in the top 0.5% in 'Extracellular Vesicles' (ScholarGPS 5/2024).
Availability
- Associate Professor Joy Wolfram is:
- Available for supervision
- Media expert
Qualifications
- Bachelor, University of Helsinki*
- Masters (Coursework), University of Helsinki*
- Doctor of Philosophy, University of the Chinese Academy of Science
- Member, Global Young Academy, Global Young Academy
- Honorary Academic, Houston Methodist Hospital, Houston Methodist Hospital
- Member, The Swedish Academy of Engineering Sciences in Finland, The Swedish Academy of Engineering Sciences in Finland
Works
Search Professor Joy Wolfram’s works on UQ eSpace
2020
Conference Publication
Therapeutic and diagnostic use of extracellular vesicles
Wolfram, Joy (2020). Therapeutic and diagnostic use of extracellular vesicles. University of Florida Infectious Diseases and Immunology Seminar Series, Gainesville, FL USA/Virtual, September 2020.
2020
Journal Article
Glycan node analysis of plasma-derived extracellular vesicles
Walker, Sierra A., Aguilar Díaz De León, Jesús S., Busatto, Sara, Wurtz, Gregory A., Zubair, Abba C., Borges, Chad R. and Wolfram, Joy (2020). Glycan node analysis of plasma-derived extracellular vesicles. Cells, 9 (9) 5277, 1946-15. doi: 10.3390/cells9091946
2020
Journal Article
Lipoprotein-based drug delivery
Busatto, Sara, Walker, Sierra A., Grayson, Whisper, Pham, Anthony, Tian, Ming, Nesto, Nicole, Barklund, Jacqueline and Wolfram, Joy (2020). Lipoprotein-based drug delivery. Advanced drug delivery reviews, 159, 377-390. doi: 10.1016/j.addr.2020.08.003
2020
Conference Publication
Extracellular vesicle therapeutics
Wolfram, Joy (2020). Extracellular vesicle therapeutics. University of North Carolina at Chapel Hill Rising Stars in Drug Delivery Seminar Series, Chapel Hill, NC USA/Virtual, July 2020.
2020
Conference Publication
Extracellular vesicle therapeutics
Wolfram, Joy (2020). Extracellular vesicle therapeutics. City University of New York Converge to Transform, New York City, NY, United States, June 2020.
2020
Conference Publication
Education and Outreach Unit
Wolfram, Joy (2020). Education and Outreach Unit. National Cancer Institute Physical Sciences-Oncology Network Site Visit, Houston, TX USA/Virtual, April 2020.
2020
Conference Publication
Regenerative medicine therapy: adipose derived extracellular vesicles in viral myocarditisRegenerative medicine therapy: adipose derived extracellular vesicles in viral myocarditis
Gorelov, D., Di Florio, Damian, Salomon, G.R., Jain, A., Saikaili, N.E., Beetler, Danielle, Shrestha, S., Tian, Ming, Wolfram, Joy and Fairweather, DeLisa (2020). Regenerative medicine therapy: adipose derived extracellular vesicles in viral myocarditisRegenerative medicine therapy: adipose derived extracellular vesicles in viral myocarditis. 2020 Soars Virtual Conference, Jacksonville, FL, United States , April 2020.
2020
Conference Publication
Potential prophylactic and therapeutic effects of (hydroxy)chloroquine against SARS-CoV-2
Wolfram, Joy (2020). Potential prophylactic and therapeutic effects of (hydroxy)chloroquine against SARS-CoV-2. Mayo Clinic Basic Science Mini-Symposium on COVID-19, Rochester, Minn, United States [virtual] , April 2020.
2020
Journal Article
Insights from nanomedicine into chloroquine efficacy against COVID-19
Hu, Tony Y., Frieman, Matthew and Wolfram, Joy (2020). Insights from nanomedicine into chloroquine efficacy against COVID-19. Nature Nanotechnology, 15 (4), 247-249. doi: 10.1038/s41565-020-0674-9
2020
Journal Article
Adipose-derived biogenic nanoparticles for suppression of inflammation
Tian, Ming, Ticer, Taylor, Wang, Qikun, Walker, Sierra, Pham, Anthony, Suh, Annie, Busatto, Sara, Davidovich, Irina, Al-Kharboosh, Rawan, Lewis-Tuffin, Laura, Ji, Baoan, Quinones-Hinojosa, Alfredo, Talmon, Yeshayahu, Shapiro, Shane, Rueckert, Felix and Wolfram, Joy (2020). Adipose-derived biogenic nanoparticles for suppression of inflammation. Small, 16 (10) 1904064, 1-13. doi: 10.1002/smll.201904064
2020
Journal Article
The solid progress of nanomedicine
Martins, João Pedro, das Neves, José, de la Fuente, María, Celia, Christian, Florindo, Helena, Günday-Türeli, Nazende, Popat, Amirali, Santos, José Luis, Sousa, Flávia, Schmid, Ruth, Wolfram, Joy, Sarmento, Bruno and Santos, Hélder A. (2020). The solid progress of nanomedicine. Drug Delivery and Translational Research, 10 (3), 726-729. doi: 10.1007/s13346-020-00743-2
2020
Conference Publication
Synthetic and biological nanoparticles for cancer and inflammatory conditions
Wolfram, Joy (2020). Synthetic and biological nanoparticles for cancer and inflammatory conditions. Nanoscience Seminar, New York, NY, United States, 27 March 2020. New York, NY, United States: City University of New York.
2020
Conference Publication
TED TALK: the future of nanomedicine
Wolfram, Joy (2020). TED TALK: the future of nanomedicine. Mayo Clinic Obstetrics/Gynecology Clinical and Surgical Updates: Staying Current and Ahead of the Curve 2020, Jacksonville, FL, United States , 17 February 2020. Jacksonville, FL, United States: Mayo Clinic.
2020
Conference Publication
The magic of nanoparticles and cancer
Wolfram, Joy (2020). The magic of nanoparticles and cancer. Inspire2Live Annual Congress, Amsterdam, Netherlands , January 2020.
2020
Conference Publication
Hybrid nanocarrier library based biomaterials for therapeutic applications
Iannotta, Dalila, Celia, Christian, Wolfram, Joy, Agata, P. and Di Marzio, Luisa (2020). Hybrid nanocarrier library based biomaterials for therapeutic applications. 1st International Northern Southern Europe Workshop in Nanomedicine, Chieti, Italy, January 2020.
2019
Conference Publication
Extracellular vesicles for therapeutic and diagnostic use
Wolfram, Joy (2019). Extracellular vesicles for therapeutic and diagnostic use. Oslo Science Park Symposium in Molecular Medicine and Precision Medicine, Oslo, Norway , December 2019.
2019
Conference Publication
Extracellular vesicles for therapeutic and diagnostic use
Wolfram, Joy (2019). Extracellular vesicles for therapeutic and diagnostic use. University of Pennsylvania Annual Symposium of the Center for Targeted Therapeutics and Translational Nanomedicine, Philadelphia, PA, United States, December 2019.
2019
Conference Publication
Nanomedicine for cancer and beyond
Wolfram, Joy (2019). Nanomedicine for cancer and beyond. Pharmatest Seminar Series, Turku, Finland, December 2019.
2019
Conference Publication
Three emerging concepts in clinical nanomedicine
Wolfram, Joy (2019). Three emerging concepts in clinical nanomedicine. University of Washington, Seattle, WA USA, December 2019.
2019
Conference Publication
Three emerging concepts in clinical nanomedicine
Wolfram, Joy (2019). Three emerging concepts in clinical nanomedicine. Fralin Biomedical Research Institute, Roanoke, VA, United States , November 2019.
Funding
Current funding
Past funding
Supervision
Availability
- Associate Professor Joy Wolfram is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Available projects
-
Developing extracellular vesicle therapeutics for cardiovascular inflammation
Every 12 minutes, one Australian dies of cardiovascular disease, accounting for 40,000+ annual deaths at a cost of $11.8B/year. Want to help us develop treatments for cardiovascular disease, the leading cause of death worldwide?
Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle therapeutics for inflammatory cardiovascular disease.
Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional medicines due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading (including RNA) of extracellular vesicles to alter the trajectory of cardiovascular disease, improve patient outcomes, and prolong healthy lifespan.
This project involves designing hybrid drug delivery systems with extracellular vesicles and synthetic components for a 'best-of-both-worlds' approach to treat cardiovascular disease.
LONG-TERM GOALS
1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat cardiovascular inflammation.
2) Save lives by manufacturing at scale - Deliver national manufacturing innovation and a skilled workforce.
3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.
-
Developing extracellular vesicle therapeutics for aging kidney disease
In the upcoming decades, health care systems are predicted to collapse due to aging-associated diseases. Chronickidney disease is on the rise in the aging population and currently affects an estimated 1.7M Australians at a cost of $1.9B annually.
Want to help us develop treatments for aging kidney disease? Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle therapeutics for aging kidney disease.
Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional medicines due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading (including RNA) of extracellular vesicles to alter the trajectory of aging diabetic kidney disease, improve patient outcomes, and prolong healthy lifespan.
This project involves designing hybrid drug delivery systems with extracellular vesicles and synthetic components for a 'best-of-both-worlds' approach to treat aging kidney disease.
LONG-TERM GOALS
1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat aging kidney disease.
2) Save lives by manufacturing at scale - Deliver national manufacturing innovation and a skilled workforce.
3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.
-
Understanding the contribution of extracellular vesicles in breast cancer immunoevasion
The deadliest breast cancer is the triple-negative subtype, which has few treatment options. New treatments are urgently needed to prevent deaths and improve the quality of life for the 3,000 Australians who are diagnosed with triple-negative breast cancer every year.
Want to help us develop treatments for deadly breast cancer? Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle-informed understanding and therapeutics for breast cancer.
The immune system is known to play a critical role in detecting and eliminating breast cancer cells and the Wolfram Laboratory has shown that triple-negative breast cancer cells release extracellular vesicles with harmful biomolecules that help the cancer cells avoid detection and destruction by the immune system. The project involves assessing how these extracellular vesicles affect the ability of immune cells to destroy breast cancer cells. The project also involves the development of new treatment options for breast cancer, including engineering natural killer cells to be resistant to extracellular vesicle-mediated suppression.
The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and targeting of extracellular vesicles to alter the trajectory of breast cancer, improve patient outcomes, and prolong healthy lifespan.
LONG-TERM GOALS
1) Uncover the mechanisms by which breast cancer extracellular vesicles suppress the immune system.
2) Develop a new paradigm of therapeutics (using engineered immune cells) to treat triple negative breast cancer.
3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.
Supervision history
Current supervision
-
Doctor Philosophy
Engineered Extracellular Vesicles for Synergistic Myocardial Infarction Therapy
Principal Advisor
-
Doctor Philosophy
Maximising the success of cancer immunotherapy by preventing extracellular vesicle hijacking of the immune system
Principal Advisor
Other advisors: Dr Allie Lam, Dr Zhengni Liu
-
Doctor Philosophy
The extracellular vesicle bio-nano interactome in cancer metastasis.
Principal Advisor
-
Doctor Philosophy
Extracellular vesicle-based senotherapeutics for aging diabetic kidney disease
Principal Advisor
Other advisors: Dr Zhengni Liu
-
Doctor Philosophy
Mutation Targeting Therapy for Cancer with dCas9
Principal Advisor
Media
Enquiries
Contact Associate Professor Joy Wolfram directly for media enquiries about:
- Biomanufacturing
- Bioseparation
- Biotherapeutics
- Breast cancer
- Exosomes
- Extracellular vesicles
- Nanomedicine
- Nanoparticles
- Regenerative medicine
- Scientific outreach
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: